Align Technology (ALGN) Q2 2026 Earnings Call Transcript
Align Technology (ALGN) reported Q2 2026 revenue of $1,056.2 million, up 4.3% y/y, driven by record Clear Aligner volumes and higher ASPs. Clear Aligner revenue rose 8.2% to $870.9 million on 691,785 cases. Systems and Services revenue fell 10.8% to $185.3 million. Q3 revenue guidance is $1.00 to $1.02 billion; full-year growth 3% to 4%.
How this was made
The 30-second read
Why it matters
Key decision points for traders are the Q3 revenue range, full-year growth outlook, margin improvement target, and the quantified UK VAT liability plus appeal uncertainty.
Market read
ALGN’s earnings include both upside drivers (record Clear Aligner volumes, margin expansion) and downside risks (Systems and Services softness, UK VAT overhang, scanner leasing revenue trade-off).
What to watch
Systems and Services revenue decline is attributed to capital equipment softness and a shift to leasing; traders should separate underlying scanner demand from accounting timing of upfront revenue.
Background
This is a transcript-style earnings call summary for Align Technology’s Q2 2026 results, including segment performance, guidance, and discussion of a UK VAT tribunal ruling.
Ticker impact
Align reported Q2 2026 revenue of $1.056B, guided Q3 revenue to $1.00B-$1.02B, and flagged a $37.5M UK VAT liability.
Likely choppy reaction with focus on Q3 revenue range, margin trajectory, and the magnitude/timing of the UK VAT appeal outcome.
The article contains a full earnings call summary with quantified results, explicit Q3 and full-year guidance, and a specific regulatory/tax overhang (UK Upper Tribunal VAT ruling) that can affect cash taxes and risk premium.
Market effects
Dental aligner and digital dentistry peers may see read-across on demand durability (Clear Aligner volumes) versus scanner monetization shifts (leasing/rental).
International growth is emphasized (APAC and EMEA shipments; teen cases adoption in China and Brazil), which can influence regional demand expectations for aligner makers.
UK VAT treatment uncertainty highlights cross-border regulatory/tax risk for medical device classifications, relevant to other medtech/dental categories.
Counterpoint
The UK VAT liability is an estimate and management intends to appeal, so the market may over-discount near-term cash impact versus the longer-dated resolution.
Key entities
- companyAlign Technology
Reported Q2 2026 results, issued Q3 and full-year guidance, and discussed a UK VAT ruling creating a $37.5M estimated liability.
- activist/investorElliott Management
Referenced as part of discussions leading to an increased share repurchase commitment.
- regulator/courtUK Upper Tribunal
Overturned a prior decision on VAT-exempt status for clear aligners, driving the estimated tax liability.
